Armis Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Armis Advisers's XBI Position: Q3 2026 in Review
Armis Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3.1% in Q3 2026, buying an estimated $7.42K and bringing the position to 1,575 shares worth $238K. The position accounts for 0.02% of the portfolio, ranked #431.
Armis Advisers first reported a position in XBI in Q2 2026 and has held it in 2 quarters since. The position peaked at $246K in Q2 2026. 964 funds tracked by Wall St. Rank hold XBI as of Q3 2026.
- Armis Advisers held 1,575 shares of State Street SPDR S&P Biotech ETF worth $238K as of Q3 2026.
- Armis Advisers bought 47 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $7.42K.
- State Street SPDR S&P Biotech ETF made up 0.02% of Armis Advisers's portfolio in Q3 2026, its #431 holding.
- Armis Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q2 2026 and has held it in 2 quarters since.
- Armis Advisers's State Street SPDR S&P Biotech ETF position peaked at $246K in Q2 2026.
- 964 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.
Based on Armis Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.